J&J-backed Bright Peak secures $90m to advance immunoconjugate programme

The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.

Jun 12, 2024 - 04:00

J&J-backed Bright Peak secures $90m to advance immunoconjugate programme

The funds will be used to advance PD1-IL18 immunoconjugate BPT567 into early-stage trials for solid tumours.

Read the original article

Tags:

Previous Article

UK clinical trial sector must address prolonged timelines, say experts

Amphastar Pharmaceuticals gets grant for medication container assembly with cap ...

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

RiMO-301 by Rimo Therapeutics for Recurrent Head And Ne...

Dec 4, 2023

STAT+: Merck CEO refused to testify in Senate because he’s not an expert in drug pricing, Bernie Sanders says

STAT+: Merck CEO refused to testify in Senate because h...

Jan 28, 2024

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024